Valuation: Paradigm Biopharmaceuticals Limited

Market Cap 99.38M 69.49M 61.04M 56.76M 52.09M 97.87M 6.69B 674M 263M 3.29B 261M 255M 11.38B P/E 2026 *
-1.78x
P/E 2027 * -1.78x
Enterprise Value 65.38M 45.72M 40.15M 37.34M 34.27M 64.38M 4.4B 443M 173M 2.16B 172M 168M 7.48B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
91.43%
Yield 2026 *
-
Yield 2027 * -
1 day-5.71%
1 week-2.94%
1 month+3.12%
3 months-26.67%
6 months-49.23%
Current year-51.47%
1 week 0.16
Extreme 0.165
0.18
1 month 0.16
Extreme 0.155
0.18
Current year 0.14
Extreme 0.135
0.37
1 year 0.14
Extreme 0.135
0.47
3 years 0.14
Extreme 0.135
0.94
5 years 0.14
Extreme 0.135
2.69
10 years 0.14
Extreme 0.135
4.5
Manager TitleAgeSince
Chief Executive Officer - 2022-11-21
Director of Finance/CFO - 2023-03-02
Chief Operating Officer - -
Director TitleAgeSince
Chairman - -
Director/Board Member 60 2020-12-08
Director/Board Member - 2024-03-03
Date Insider Type Main position Quantity % Market Cap.
6/29/26 Expiration

Chief Executive Officer

-600,000 0.1026%
6/18/26 Free

Chief Executive Officer

176,470 0.0336%
6/18/26 Free

Director

176,470 0.0336%
Change 5-day change 1-year change 3-year change Capi.($)
-5.71%-2.94%-61.63%-82.35% 69.49M
+1.07%-3.49%-3.35%+10.44% 46.86B
+0.25%+1.65%+399.22%+634.87% 40.23B
-0.27%+4.45%+11.81%+65.64% 36.23B
+0.35%+0.87%+4.46%-10.16% 34.72B
+3.14%+1.02%+4.76%+40.92% 27.89B
-0.73%+11.84%+34.39%+134.36% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%-3.43%+9.03% 13.12B
-2.68%-2.49%-11.36%-33.61% 12.7B
Average -0.37%+0.45%+41.65%+85.46% 24.53B
Weighted average by Cap. +0.48%+0.91%+74.37%+136.21%

Financials

2026 *2027 *
Net sales - -
Net income -36.3M -25.38M -22.3M -20.73M -19.03M -35.75M -2.44B -246M -96.19M -1.2B -95.29M -93.24M -4.16B -44.8M -31.33M -27.52M -25.59M -23.48M -44.12M -3.02B -304M -119M -1.48B -118M -115M -5.13B
Net Debt -34M -23.78M -20.88M -19.42M -17.82M -33.48M -2.29B -231M -90.1M -1.13B -89.26M -87.33M -3.89B -12M -8.39M -7.37M -6.85M -6.29M -11.82M -808M -81.39M -31.8M -397M -31.5M -30.82M -1.37B
Logo Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited is a late-stage drug development company engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). PPS is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans. It develops PPS under the brand name Zilosul. Other indications under investigation for PPS include the treatment of joint function, mobility, and pain in patients with mucopolysaccharidoses; treating alphavirus-induced arthralgia; chronic heart failure; acute respiratory distress syndrome; and allergic respiratory conditions. It is also advancing early formulation development for Pentacoxib, an oral combination of PPS and a COX-2 inhibitor targeting patients with earlier-stage OA.
Employees
-
Date Price Change Volume
26-07-24 A$0.1650 -5.71% 1,775,603
26-07-23 A$0.1750 0.00% 803,547
26-07-22 A$0.1750 +6.06% 989,010
26-07-21 A$0.1650 0.00% 1,168,559
26-07-20 A$0.1650 -2.94% 1,010,250
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.1650AUD
Average target price
1.095AUD
Spread / Average Target
+563.64%

Annual profits - Rate of surprise